“UROKRAFT” is a detailed comprehensive signature project developed under the category of Continuous Professional Development (CPD) program in association with global reputed institutions specialized in Urology and Oncology.
UROKRAFT is led by International Key Thought Leaders in the field of Urology and Oncology, its management and research. Urokraft mentors conduct professional development programs across the world to develop early opinion leadership amongst urologists and oncologists. Urokraft board also includes senior urology and oncology experts from India for assisting collaborative learning on uro-oncology.
UROKRAFT is an exclusive multi-mentor led International educational opportunity specifically designed for upskill and knowledge enhancement among clinicians in India. The program engages mentors from the United States, Europe and India.
WEbRx stands as a prominent professional medical education organization with a global presence across the USA, EU, GCC, and the Emerging East. Our extensive reach is facilitated by a Key Thought Leader network, fostering close connections with various stakeholders in healthcare practice worldwide. Committed to upholding the highest academic standards, we specialize in continuous professional development and personalized medical education and training programs.
Since our establishment, WEbRx has successfully conducted educational programs in 40 countries, establishing partnerships with numerous Global Academic Institutes, with the number still growing. Our programs extend into emerging and challenging therapeutic areas, collaborating with Global Medical Accreditation Authorities. We take pride in implementing integrated disease management solutions through our practice ecosystems across different countries.
One of our flagship initiatives, the UROKRAFT course, is a collaborative effort involving WEbRx USA Incorporation and experts from renowned institutions such as Mayo Clinic, City Of Hope, UCL University, Belgium, Basavatarakam Indo American Cancer Hospital and Research Institute, and Nanavati Hospital.
Organizing Team Dr. Alan H. Bryce (Program Director) Dr. Senthil J Rajappa (Program Joint Director)
Dr. Nagraj Huilgol (Program Mentor)
Dr. Senthil Rajappa (Program Joint Director)
Prof. Dr. Bertrand Tombal (Program Mentor)
Dr. Senthil Rajappa (Program Joint Director) Dr. Nagraj Huilgol (Program Mentor)
Organizing Team
Dr. Alan H. Bryce (Program Director)
Dr. Senthil J Rajappa (Program Joint Director)
Dr. Alton O. Sartor (Program Mentor)
Dr. Senthil Rajappa (Program Joint Director) Dr. Nagraj Huilgol (Program Mentor)
Organizing Team
Dr. Alan H. Bryce (Program Director)
Prof. Dr. Bertrand Tombal (Program Mentor)
Dr. Alton O. Sartor (Program Mentor)
Dr. Senthil Rajappa (Program Joint Director) Dr. Nagraj Huilgol (Program Mentor)
Dr. Alan H. Bryce (Program Director)
Dr. Alan H. Bryce (Program Director)
Dr. Senthil J Rajappa (Program Joint Director)
Prof. Dr. Bertrand Tombal (Program Mentor)
Dr. Nagraj Huilgol (Program Mentor)
Guidance for the management of low-risk localized prostate cancer will be coordinated by the urology team, covering options such as surgery, radiation, and active surveillance. While active surveillance is less common in India due to limited screening.
This section will delve into surgical, radiation, and active surveillance strategies. Notably, active surveillance is less prevalent in India due to screening challenges.
Emphasizing multi modal therapy involving surgery, radiation, and medical oncology.
Focus on salvage radiation as the initial step, followed by systemic therapy post- radiation. Although this may represent a smaller portion of Indian uro-oncology practice.
A crucial topic for the Indian audience, given the high incidence of metastatic disease at initial presentation. One mentor proposes leading this personally, drawing on extensive experience in the field.
Acknowledging the audience's familiarity, this remains an essential topic.
A specialist's perspective, delving beyond standard care to provide a comprehensive understanding of somatic NGS in prostate cancer.
Discussion on the latest data involving four drugs, with the potential for extensive discourse due to existing controversies.
Discussion on the use of PSMA imaging.
Important discussion by multiple Mentors
Acknowledging the extensive use of docetaxel in India, a master perspective will be provided on its role in metastatic castration-resistant prostate cancer (mCRPC).
Emphasis on personalized management of CV Risk in Ca Prostrate and Pharmacotherapy in Cardiovascular and Prostate Cancer.
Mastering Transperineal Biopsy
Any Queries? Whatsapp Me!
